Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Importance Pituitary adenomas may hypersecrete hormones or cause mass effects.
Therefore, early diagnosis and treatment are important. Observations Prevalence of pituitary …

Multiple endocrine neoplasia type 1 (MEN1), a rare tumor syndrome that is inherited in an
autosomal dominant pattern, is continuing to raise great interest for endocrinology …

Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of
somatotropinomas, thyrotropinomas, and functioning and non-functioning …

Pituitary apoplexy, a rare clinical syndrome secondary to abrupt hemorrhage or infarction,
complicates 2%–12% of pituitary adenomas, especially nonfunctioning tumors. Headache of …

abstract Objective: The aim was to formulate practice guidelines for the diagnosis and
treatment of hyperprolactinemia. Participants: The Task Force consisted of Endocrine …

Prevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new
cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced …

Hyperprolactinaemia is one of the most common problems in clinical endocrinology. It
relates with various aetiologies (physiological, pharmacological, pathological), the …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

The WHO categorizes pituitary tumours as typical adenomas, atypical adenomas and
pituitary carcinomas, with typical adenomas constituting the major class. However, the WHO …